10-Q: Alkermes Reports Q3 2025 Results, Announces Avadel Acquisition

Alkermes plc reported a decrease in net income from continuing operations for the nine months ended September 30, 2025, while announcing a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $20.00 per share.

Summary

• Net income from continuing operations for the nine months ended September 30, 2025, was $192.3 million, a decrease from $226.4 million in the same period of 2024.
• Total revenues for the nine months ended September 30, 2025, were $1,091.4 million, down from $1,127.6 million in 2024, primarily due to lower manufacturing and royalty revenues.
• Product sales, net, increased by $93.3 million to $869.2 million for the nine months ended September 30, 2025, driven by VIVITROL, ARISTADA/ARISTADA INITIO, and LYBALVI.
• Manufacturing and royalty revenues decreased by $129.6 million to $222.2 million, largely due to the expiration of the INVEGA SUSTENNA royalty in the U.S. in August 2024.
• Research and development expenses increased by $43.8 million to $230.9 million, mainly due to the advancement of the Alixorexton development program and preclinical activities.
• Selling, general and administrative expenses rose by $16.1 million to $514.3 million, primarily due to increased headcount in sales, marketing, and general administration.
• Cash and cash equivalents significantly increased to $616.4 million as of September 30, 2025, from $291.1 million at December 31, 2024.
• The company entered into an agreement to acquire Avadel Pharmaceuticals plc for a total potential consideration of up to $20.00 per Avadel Share, expected to close in Q1 2026.
• An Authorized Generic Product Supply Agreement for VIVITROL was signed with Amneal Pharmaceuticals LLC, with a target launch date of January 15, 2027, contingent on a third-party generic launch.
• The Alixorexton development program is proceeding to Phase 3 in narcolepsy following positive Phase 2 Vibrance-1 study results.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag. While proprietary product sales are growing and the Alixorexton program is advancing, overall revenue and net income are down due to royalty expirations. The Avadel acquisition is a significant strategic move with potential, but also introduces substantial debt and integration risks. Legal challenges also add uncertainty.

Positives

• Product sales, net, increased by $93.3 million to $869.2 million for the nine months ended September 30, 2025, demonstrating strong performance from proprietary products.
• LYBALVI sales grew by $49.5 million to $252.6 million for the nine months ended September 30, 2025, reflecting a 19% increase in units sold and a 3% price increase.
• VIVITROL sales increased by $20.6 million to $343.8 million for the nine months ended September 30, 2025, with a 2% increase in units sold and a 3% price increase.
• ARISTADA and ARISTADA INITIO sales rose by $23.2 million to $272.8 million for the nine months ended September 30, 2025, despite a 1% decrease in units sold, due to a 3% price increase.
• Cash and cash equivalents more than doubled to $616.4 million as of September 30, 2025, from $291.1 million at December 31, 2024, indicating strong liquidity.
• Cash flows provided by operating activities increased by $101.9 million to $350.7 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• Positive Phase 2 Vibrance-1 study results for Alixorexton (narcolepsy type 1) led to plans for a Phase 3 program, indicating pipeline advancement.
• The U.S. Court of Appeals for the Federal Circuit affirmed the patent validity for INVEGA TRINZA, protecting a significant royalty stream from Janssen.
• A new U.S. Patent No. 12,390,474 relating to LYBALVI was granted in August 2025, extending patent protection until 2041.
• The effective tax rate decreased to 16.8% for the nine months ended September 30, 2025, from 17.3% in 2024, partly due to windfall benefits from employee equity activity.

Negatives

• Net income from continuing operations decreased by $34.1 million to $192.3 million for the nine months ended September 30, 2025, compared to $226.4 million in the prior year.
• Total revenues decreased by $36.3 million to $1,091.4 million for the nine months ended September 30, 2025, primarily due to a significant drop in manufacturing and royalty revenues.
• Manufacturing and royalty revenues from long-acting INVEGA products decreased by $121.6 million to $78.3 million, mainly due to the expiration of the INVEGA SUSTENNA royalty in the U.S. in August 2024.
• Research and development expenses increased by $43.8 million, impacting profitability.
• Selling, general and administrative expenses increased by $16.1 million, contributing to higher overall expenses.
• The company settled VUMERITY ANDA litigation, granting Zydus a license to launch a generic version prior to patent expiration under certain circumstances, indicating future generic competition.
• An antitrust class action lawsuit was filed against the company regarding VIVITROL, alleging fraudulent patent practices and seeking unspecified money damages.
• The company expects to incur $15.0 million to $20.0 million in costs related to the Avadel acquisition during Q4 2025.
• The company's debt obligations could adversely affect its business, and failure to secure permanent financing for the Avadel acquisition could lead to significantly higher borrowing costs under the bridge credit facility.

Risks

• Inability to complete the proposed acquisition of Avadel Pharmaceuticals plc on contemplated timelines or at all, due to conditions like shareholder approval, Irish High Court sanction, or antitrust clearances.
• Failure to realize anticipated benefits and synergies from the Avadel acquisition, or difficulties in integrating Avadel's business, which could adversely affect business and financial condition.
• Debt obligations from the $1.2 billion bridge credit facility for the Avadel acquisition could adversely affect the business and limit ability to respond to changes, with potential for higher borrowing costs if permanent financing is not secured.
• Changes in global trade or other policies, including tariffs or restrictions, could adversely affect business, results of operations, or financial condition, especially given international sourcing and manufacturing of certain third-party products.
• Uncertainty over intellectual property in the biopharmaceutical industry, leading to litigation and competition from generic drug manufacturers, as evidenced by ongoing ANDA litigations for LYBALVI and INVEGA products.
• Litigation or arbitration, including product liability cases (e.g., VIVITROL), antitrust claims, and regulatory actions, may result in financial losses, harm reputation, or divert management resources.
• Increased competition from new products or generic versions of long-acting INVEGA products may lead to reduced unit sales and increased pricing pressure, following the expiration of the INVEGA SUSTENNA royalty.
• The Authorized Generic Product Supply Agreement for VIVITROL with Amneal is contingent on a third-party ANDA product launch, and a 'Third Party ANDA Product Launch Failure' would prevent Amneal from launching the authorized generic.

Future Outlook

The company expects the proposed acquisition of Avadel Pharmaceuticals plc to be completed in the first quarter of 2026, incurring $15.0 million to $20.0 million in related costs during Q4 2025. Royalty revenues from long-acting INVEGA products are expected to continue to be lower in 2025 due to the expiration of the INVEGA SUSTENNA royalty. The One Big Beautiful Bill Act (OBBBA) is expected to materially increase cash flows provided by operating activities and materially decrease net U.S. deferred tax assets over the next number of years. The company plans to initiate a Phase 3 program for Alixorexton in narcolepsy.

Management Comments

• Management expects the Proposed Acquisition to be completed in the first quarter of 2026.
• Management expects to incur costs of approximately $15.0 million to $20.0 million in connection with the Proposed Acquisition during the fourth quarter of 2025.
• Management expects royalty revenues from net sales of the long-acting INVEGA products to continue to be lower in 2025 due to the expiration of the INVEGA SUSTENNA royalty.
• Management intends to vigorously defend its intellectual property in the LYBALVI ANDA litigation.
• Management intends to vigorously defend itself in the VIVITROL antitrust class action litigation and other legal proceedings.
• Management expects that the provisions in the OBBBA will result in a material increase in cash flows provided by operating activities and a material decrease in net U.S. deferred tax assets over the next number of years.
• Management expects existing cash, cash equivalents, and investments to be sufficient to finance anticipated working capital and other cash requirements for not less than twelve months.

Industry Context

The biopharmaceutical industry continues to face challenges from patent expirations and generic competition, as evidenced by the VUMERITY settlement and ongoing ANDA litigations for LYBALVI and INVEGA products. However, innovation in neuroscience, such as Alkermes' Alixorexton program, remains a key growth driver. Strategic acquisitions, like the proposed Avadel deal, reflect a trend of companies seeking to expand their product portfolios and market reach to offset revenue declines from mature products. The focus on long-acting injectables and combination therapies for psychiatric and neurological disorders aligns with industry efforts to improve patient adherence and outcomes.

Comparison to Industry Standards

• The decline in overall revenue, primarily due to the expiration of the INVEGA SUSTENNA royalty, is a common challenge for pharmaceutical companies as products lose patent exclusivity. This is comparable to other companies facing 'patent cliffs' for blockbuster drugs.
• The growth in proprietary product sales (VIVITROL, ARISTADA, LYBALVI) indicates successful commercialization efforts, which is a positive sign in a competitive market. LYBALVI's 19% unit sales increase is strong, potentially outperforming some new drug launches in its therapeutic area.
• Increased R&D spending, particularly on Alixorexton, is consistent with industry trends where companies invest heavily in pipeline development to secure future growth, especially in high-need areas like narcolepsy and idiopathic hypersomnia.
• The proposed acquisition of Avadel, a company focused on sleep disorders, suggests a strategic move to diversify and strengthen the neuroscience portfolio, a common strategy among mid-to-large cap biopharma firms seeking bolt-on acquisitions to add late-stage or recently approved assets.
• The ongoing ANDA litigations for LYBALVI and INVEGA products are standard industry practice for protecting intellectual property against generic challenges, reflecting the high value of these branded assets. The VUMERITY settlement, allowing earlier generic entry, is a less favorable but sometimes necessary outcome in patent disputes.

Management Changes

Corporate Governance

Legal Proceedings

• INVEGA TRINZA ANDA Litigation: U.S. Court of Appeals for the Federal Circuit affirmed the NJ District Court's decision in favor of Janssen (Alkermes' licensee) regarding patent infringement by Mylan Labs. Mylan's petition for rehearing was denied on July 1, 2025.
• VUMERITY ANDA Litigation: Settlement agreement reached with Zydus on July 21, 2025, granting Zydus a license to commercialize a generic version of VUMERITY in the U.S. beginning on an agreed date prior to patent expiration.
• LYBALVI ANDA Litigation: Patent infringement lawsuits filed against Teva, Apotex, and MSN in August/September 2025 following their ANDA filings. These lawsuits triggered 30-month stays of FDA approval.
• Antitrust Class Action Litigation: Value Drug Company filed a complaint on October 2, 2025, alleging fraudulent obtainment, listing, and enforcement of the VIVITROL patent, seeking unspecified money damages.
• Product Liability and Other Legal Proceedings: Ongoing litigation, including a product liability case alleging VIVITROL caused opioid overdose and death.

Stakeholder Impact

• Shareholders: Potential for increased value from the Avadel acquisition and Alixorexton pipeline advancement, but also face risks from increased debt, integration challenges, and ongoing legal proceedings impacting revenue streams.
• Employees: Management changes with a new CFO, and an increase in R&D and sales/marketing headcount, indicating growth and investment in human capital. The amended stock plan provides more equity incentives.
• Customers: Continued availability of proprietary products (VIVITROL, ARISTADA, LYBALVI) and potential new treatments from the Alixorexton program. Generic competition for VUMERITY may lead to lower prices.
• Competitors: The Avadel acquisition and Alixorexton's progression could intensify competition in neuroscience and sleep disorder markets. Generic challenges to Alkermes' products highlight the competitive landscape.
• Regulatory Authorities: Ongoing engagement through ANDA litigations and compliance with new accounting standards (e.g., OBBBA's tax implications).

Next Steps

• Complete the proposed acquisition of Avadel Pharmaceuticals plc, expected in Q1 2026.
• Initiate a Phase 3 program for Alixorexton in narcolepsy.
• Continue to vigorously defend intellectual property in LYBALVI ANDA litigation against Teva, Apotex, and MSN.
• Vigorously defend against the VIVITROL antitrust class action litigation.
• Manage the launch of the VIVITROL authorized generic product by Amneal Pharmaceuticals LLC, contingent on a third-party generic launch by January 15, 2027.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-06) on consolidated financial statements and disclosures.

Key Dates

Recommendation

The filing presents a complex picture. While Alkermes' proprietary product sales are growing and the Alixorexton pipeline shows promise, the overall revenue and net income have declined due to the expiration of a significant royalty stream. The proposed acquisition of Avadel is a bold strategic move that could enhance the company's neuroscience portfolio, but it comes with substantial financial leverage from the bridge loan and inherent integration risks. The ongoing legal challenges, particularly the VIVITROL antitrust lawsuit and the VUMERITY generic settlement, introduce significant uncertainty regarding future revenue and potential liabilities. Given the mixed financial performance, the strategic but risky acquisition, and the legal headwinds, a 'hold' recommendation is appropriate. Investors should monitor the progress of the Avadel acquisition, the Alixorexton Phase 3 program, and the outcomes of the various litigations before making further investment decisions.

Keywords

Biopharmaceutical, Neuroscience, SEC Filing, 10-Q, Alkermes, Avadel, Acquisition, VIVITROL, ARISTADA, LYBALVI, Alixorexton, Narcolepsy, Schizophrenia, Bipolar I Disorder, Opioid Dependence, Alcohol Dependence, ANDA Litigation, Patent Infringement, Financial Results, Revenue, Net Income, R&D, Cash Flow, Corporate Governance, Share Repurchase, Pharmaceutical Industry